Anne-Laure Vallier

906 total citations
14 papers, 302 citations indexed

About

Anne-Laure Vallier is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Anne-Laure Vallier has authored 14 papers receiving a total of 302 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Cancer Research and 5 papers in Genetics. Recurrent topics in Anne-Laure Vallier's work include BRCA gene mutations in cancer (5 papers), Breast Cancer Treatment Studies (5 papers) and Cancer Treatment and Pharmacology (5 papers). Anne-Laure Vallier is often cited by papers focused on BRCA gene mutations in cancer (5 papers), Breast Cancer Treatment Studies (5 papers) and Cancer Treatment and Pharmacology (5 papers). Anne-Laure Vallier collaborates with scholars based in United Kingdom, Canada and Cyprus. Anne-Laure Vallier's co-authors include Helena Earl, Jean Abraham, Louise Hiller, Janet Dunn, Elena Provenzano, Carlos Caldas, S. Bowden, Paul D.P. Pharoah, Linda Jones and Susan Ingle and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Anne-Laure Vallier

13 papers receiving 299 citations

Peers

Countries citing papers authored by Anne-Laure Vallier

Since Specialization

Citations

This map shows the geographic impact of Anne-Laure Vallier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne-Laure Vallier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne-Laure Vallier more than expected).

Fields of papers citing papers by Anne-Laure Vallier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne-Laure Vallier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne-Laure Vallier. The network helps show where Anne-Laure Vallier may publish in the future.

Co-authorship network of co-authors of Anne-Laure Vallier

This figure shows the co-authorship network connecting the top 25 collaborators of Anne-Laure Vallier. A scholar is included among the top collaborators of Anne-Laure Vallier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne-Laure Vallier. Anne-Laure Vallier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	PARTNER: A randomized, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with triple-negative and/or germline BRCA-mutated breast cancer. 2022 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), Jerome Wulff, Alimu Dayimu, Nikos Demiris, Anne-Laure Vallier, Wendi Qian, Andrea Machin, Karen McAdam, Rebecca Roylance, Ellen Copson, Anne Armstrong, N C Levitt, Elena Provenzano, Marc Tischkowitz, (unknown), Helena Earl, Jean Abraham	5
2	Abstract P3-10-05: Preliminary safety data from stage 1 and 2 of the phase II/III PARTNER trial: Addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients 2020 ·Cancer Research ·(unknown), (unknown), Anne-Laure Vallier, (unknown), Ellen Copson, Anne Armstrong, Rebecca Roylance, Wendi Qian, Nikolaos Demiris, (unknown), (unknown), Luke Hughes‐Davies, Karen McAdam, (unknown), (unknown), Elena Provenzano, Marc Tischkowitz, Helena Earl, Jean Abraham	8
3	PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients. 2018 ·Journal of Clinical Oncology ·Jean Abraham, Anne-Laure Vallier, Wendi Qian, Andrea Machin, (unknown), (unknown), (unknown), Karen McAdam, Luke Hughes‐Davies, Rebecca Roylance, Ellen Copson, Elena Provenzano, (unknown), (unknown), Marc Tischkowitz, Helena Earl	7
4	PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients. 2017 ·Journal of Clinical Oncology ·Helena Earl, Anne-Laure Vallier, Wendi Qian, (unknown), (unknown), (unknown), (unknown), Karen McAdam, Luke Hughes‐Davies, Rebecca Roylance, Ellen Copson, Jessica Brown, Elena Provenzano, (unknown), Marc Tischkowitz, Jean Abraham	11
5	The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study 2016 ·PLoS ONE ·Leila Dorling, Siddhartha Kar, Kyriaki Michailidou, Louise Hiller, Anne-Laure Vallier, Susan Ingle, (unknown), S. Bowden, Janet Dunn, Chris Twelves, Christopher Poole, Carlos Caldas, Helena Earl, (unknown), Jean Abraham	8
6	Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer 2016 ·Breast Cancer Research ·H. Raza Ali, Aliakbar Dariush, Elena Provenzano, Helen Bardwell, Jean Abraham, Mahesh Iddawela, Anne-Laure Vallier, Louise Hiller, Janet Dunn, S. Bowden, Tamas Hickish, Karen McAdam, Stephen Houston, M. J. Irwin, Paul D.P. Pharoah, James D. Brenton, N. A. Walton, Helena Earl, Carlos Caldas	64
7	Disease-free (DFS) and overall survival (OS) at 3.4 years (yrs) for neoadjuvant bevacizumab (Bev) added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC), for women with HER2 negative early breast cancer: The ARTemis trial. 2016 ·Journal of Clinical Oncology ·Helena Earl, Louise Hiller, Janet Dunn, (unknown), (unknown), Anne-Laure Vallier, Jean Abraham, Luke Hughes‐Davies, Karen McAdam, Stephen Chan, Rizvana Ahmad, Tamas Hickish, Stephen Houston, Daniel Rea, John M.S. Bartlett, Carlos Caldas, David Cameron, Elena Provenzano, Jeremy Thomas, Larry Hayward, (unknown)	3
8	Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean? 2015 ·BMC Medicine ·Helena Earl, Elena Provenzano, Jean Abraham, Janet Dunn, Anne-Laure Vallier, Ioannis Gounaris, Louise Hiller	44
9	A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities 2015 ·BMC Medicine ·Jean Abraham, Louise Hiller, Leila Dorling, Anne-Laure Vallier, Janet Dunn, S. Bowden, Susan Ingle, Linda Jones, (unknown), Christopher Twelves, Christopher Poole, Paul D.P. Pharoah, Carlos Caldas, Helena Earl	25
10	A Bayesian adaptive design for biomarker trials with linked treatments 2015 ·British Journal of Cancer ·James Wason, Jean Abraham, Richard D. Baird, (unknown), Anne-Laure Vallier, James D. Brenton, Helena Earl, Adrian Mander	22
11	Abstract PD2-3: ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy for patients with HER2-negative early breast cancer 2015 ·Cancer Research ·Helena Earl, Louise Hiller, Janet Dunn, (unknown), (unknown), Anne-Laure Vallier, Jean Abraham, Jeremy Thomas, Elena Provenzano, Luke Hughes‐Davies, Karen McAdam, Stephen L. Chan, Rizvana Ahmad, Tamas Hickish, Stephen Houston, Daniel Rea, John M.S. Bartlett, Carlos Caldas, David Cameron, Larry Hayward	0
12	Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel 2014 ·Clinical Cancer Research ·Jean Abraham, Qi Guo, Leila Dorling, Jonathan P. Tyrer, Susan Ingle, (unknown), Anne-Laure Vallier, Louise Hiller, Stephen R. Russell, Linda Jones, S. Bowden, Janet Dunn, Christopher Poole, Carlos Caldas, Paul D.P. Pharoah, Helena Earl	82
13	ARTemis: A randomised trial of bevacizumab with neoadjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer—Primary endpoint, pathological complete response (pCR). 2014 ·Journal of Clinical Oncology ·Helena Earl, Louise Hiller, (unknown), (unknown), Anne-Laure Vallier, Jean Abraham, Jeremy Thomas, Elena Provenzano, Luke Hughes‐Davies, Karen McAdam, Stephen Chan, Rizvana Ahmad, Tamas Hickish, Stephen Houston, Daniel Rea, John M.S. Bartlett, Carlos Caldas, David Cameron, Janet Dunn, Richard L. Hayward, (unknown)	3
14	Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR) 2009 ·Journal of Clinical Oncology ·Helena Earl, Anne-Laure Vallier, Louise Hiller, Nicola Fenwick, Mahesh Iddawela, Luke Hughes‐Davies, Elena Provenzano, Karen McAdam, Tamas Hickish, Carlos Caldas	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact